Bifogade filer
Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2020-2022
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | Large Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Revenio Group Corporation, Stock Exchange Release, February 13, 2023 at 3.15 p.m. (EET)
Revenio Group Corporation to transfer shares related to the share-based incentive scheme for 2020-2022
The Board of Directors of Revenio Group Corporation decided, on February 13, 2023, on the basis of the share issue authorization granted to the Board of Directors by the company's Annual General Meeting held on April 8, 2022, to issue shares in a directed share issue without payment to pay the shares earned by the company’s key persons during the performance period 2020-2022 LTI of the share-based incentive scheme.
The shares to be issued in the directed share issue without payment are issued in accordance with the terms and conditions of the company's current share-based incentive scheme to enhance the stability and work motivation of personnel, and thus there is an especially weighty financial reason for the share issue and for the derogation of the pre-emptive right of shareholders as provided in Chapter 9, Section 4(1) of the Finnish Limited Liability Companies Act. The key terms of the share-based incentive plan are described in the company's 2021 Remuneration Report.
A total of 8,124 of the company’s treasury shares will be issued in a directed issue without payment to persons included in the share-based incentive scheme. After the transfers, the company holds 92,618 treasury shares.
Revenio Group Corporation
Board of Directors
For further information, please contact
President and CEO Jouni Toijala, tel. +358 50 484 0085
jouni.toijala@revenio.fi
CFO Robin Pulkkinen, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Nasdaq Helsinki Ltd
Main media
www.revenio.fi
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.